Iqvia (NYSE:IQV) had its price target hoisted by analysts at Royal Bank of Canada to $137.00 in a report issued on Tuesday, The Fly reports. The firm currently has an “outperform” rating on the medical research company’s stock. Royal Bank of Canada’s price objective would indicate a potential upside of 13.95% from the stock’s previous close.

A number of other analysts have also recently commented on IQV. ValuEngine upgraded shares of Iqvia from a “hold” rating to a “buy” rating in a research note on Thursday, July 12th. Zacks Investment Research upgraded shares of Iqvia from a “hold” rating to a “buy” rating and set a $111.00 price target for the company in a research note on Wednesday, July 4th. SunTrust Banks increased their price target on shares of Iqvia to $140.00 and gave the company a “buy” rating in a research note on Wednesday, July 25th. Stifel Nicolaus increased their price target on shares of Iqvia from $128.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 25th. Finally, Bank of America upgraded shares of Iqvia from a “neutral” rating to a “buy” rating and set a $135.00 price target for the company in a research note on Wednesday, July 25th. Four analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Iqvia presently has an average rating of “Buy” and a consensus price target of $131.32.

Iqvia stock traded down $6.22 during mid-day trading on Tuesday, reaching $120.23. The company’s stock had a trading volume of 107,290 shares, compared to its average volume of 1,028,486. The company has a market cap of $25.71 billion, a P/E ratio of 27.74, a price-to-earnings-growth ratio of 1.82 and a beta of 0.70. Iqvia has a 12 month low of $91.57 and a 12 month high of $135.48. The company has a current ratio of 1.13, a quick ratio of 1.13 and a debt-to-equity ratio of 1.40.

Iqvia (NYSE:IQV) last released its earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.03. The business had revenue of $2.59 billion during the quarter, compared to the consensus estimate of $2.58 billion. Iqvia had a net margin of 12.68% and a return on equity of 13.51%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, equities research analysts forecast that Iqvia will post 5.13 EPS for the current year.

In other news, Director Ronald A. Rittenmeyer sold 7,680 shares of the firm’s stock in a transaction dated Thursday, July 26th. The shares were sold at an average price of $122.41, for a total transaction of $940,108.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John G. Danhakl sold 370,470 shares of the firm’s stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $124.83, for a total transaction of $46,245,770.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 978,777 shares of company stock valued at $121,566,089. 6.00% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of IQV. First Trust Advisors LP acquired a new stake in Iqvia in the 2nd quarter worth about $99,127,000. Laurion Capital Management LP raised its stake in Iqvia by 188.1% in the 2nd quarter. Laurion Capital Management LP now owns 378,318 shares of the medical research company’s stock worth $37,764,000 after purchasing an additional 807,697 shares in the last quarter. BlackRock Inc. raised its stake in Iqvia by 5.7% in the 2nd quarter. BlackRock Inc. now owns 10,170,048 shares of the medical research company’s stock worth $1,015,173,000 after purchasing an additional 546,878 shares in the last quarter. Atalanta Sosnoff Capital LLC acquired a new stake in Iqvia in the 3rd quarter worth about $51,970,000. Finally, Retirement Systems of Alabama raised its stake in Iqvia by 374.0% in the 2nd quarter. Retirement Systems of Alabama now owns 330,106 shares of the medical research company’s stock worth $32,951,000 after purchasing an additional 260,467 shares in the last quarter. Institutional investors and hedge funds own 90.70% of the company’s stock.

About Iqvia

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Recommended Story: What are the benefits of a balanced fund?

The Fly

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.